Business Context and Reporting Period
This Form 6-K filing by Apollomics Inc. covers the month of September 2025, specifically reporting on corporate governance changes effective September 4, 2025. The filing details the appointment of new directors, the constitution of board committees, and the designation of key executive officers. It also includes a correction regarding beneficial ownership following a Private Investment in Public Equity (PIPE) transaction.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and ownership structure updates.
Material Changes
- Board Composition: The Board of Directors now consists of seven members. New directors appointed are Yi-An Chu and Chen-Huan Jan. The full board includes Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Po-Jen Hsueh, Hsien-Shu Tsai, Yi-An Chu, and Chen-Huan Jan.
- Executive Leadership: Hung-Wen (Howard) Chen was appointed Chairman of the Board and Chief Executive Officer. Yi-Kuei Chen was appointed Chief Operating Officer, and Peter Lin was appointed Chief Financial Officer.
- Committee Structure:
- Audit Committee: Po-Jen Hsueh, Hsien-Shu Tsai (Chairman), and Yi-An Chu.
- Compensation Committee: Moses Chen (Chairman), Hsien-Shu Tsai, and Yi-An Chu.
- Nominating and Corporate Governance Committee: Moses Chen, Po-Jen Hsueh, and Chen-Huan Jan (Chairman).
- Ownership Correction: A correction was issued regarding a previous filing. Hung-Wen (Howard) Chen and his affiliates beneficially own approximately 42% of the outstanding Class A ordinary shares. Maxpro Investment Co., Ltd. and its affiliates beneficially own approximately 4.9% of the outstanding Class A ordinary shares.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors. However, the biographical information highlights that Chairman Howard Chen previously led a strategic reorganization of Polaris Pharmaceuticals during a severe financial crisis, suggesting a management team with experience in turnaround situations. The filing notes that information regarding PIPE Subscription Agreements is incorporated by reference into the Company's registration statements.
Investor Verification Checklist
- Verify the exact terms of the PIPE Subscription Agreements referenced in the filing.
- Confirm the total outstanding share count to validate the 42% and 4.9% beneficial ownership percentages.
- Review the Company's most recent Form 20-F or 10-K for actual financial performance data, as this 6-K contains none.
- Assess the strategic fit of the new CFO (Peter Lin) and COO (Yi-Kuei Chen) given their backgrounds in biotechnology and venture capital.